Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment

John Storwick, Carrie Ye, Shahin Jamal, Nancy Maltez, Mercedes ChanPediatric 2025 · DOI

Abstract

Significant knowledge gaps and a lack of confidence exist among pediatric rheumatologists (PRs) managing immune checkpoint inhibitor (ICI)-related rheumatic immune-related adverse events (Rh-irAEs). As ICI use increases in pediatric oncology, PRs' exposure to Rh-irAEs will follow. This study highlights an urgent need for targeted educational programs and pediatric-specific clinical guidelines to address these gaps.

Introduction

Immune checkpoint inhibitors (ICIs) have revolutionized oncology by enhancing the immune system's ability to target tumors. However, this heightened activity often results in immune-related adverse events (irAEs). When these side effects manifest as rheumatic conditions (Rh-irAEs), such as inflammatory arthritis or myositis, pediatric rheumatologists (PRs) are essential for management.

While protocols for adult patients are increasingly standardized, the use of ICIs in children is a relatively new frontier. PRs face the complex task of managing potentially life-altering autoimmune conditions in pediatric cancer patients, often without the support of age-specific data or guidelines. This study assesses the current state of knowledge, experience, and confidence among PRs to identify critical areas for professional development.

Methods

A cross-sectional needs assessment was conducted via a 21-question online survey distributed to 2,084 pediatric rheumatologists through the "Dr. Peter Dent Pediatric Rheumatology Bulletin Board." The survey, adapted from a 2019 study of adult rheumatologists, evaluated practitioner demographics, familiarity with ICI mechanisms, clinical experience with Rh-irAEs, and self-reported management confidence. Data from 69 respondents were analyzed using descriptive statistics.

Results and Key Insights

The Awareness Gap

The study revealed a significant "readiness gap" within the specialty. Nearly half of the surveyed specialists expressed a lack of detailed knowledge regarding the drugs themselves or their associated complications.

Awareness of Immune Checkpoint Inhibitors (ICIs) among pediatric rheumatologists.

Specifically, 49.3% of respondents were either completely unaware of ICIs or lacked knowledge of their indications and mechanisms. This gap extended to the complications: 58% of participants were unfamiliar with the details of irAEs or had never heard of them.

Awareness of immune-related adverse events (irAEs) among pediatric rheumatologists.

Clinical Experience and Confidence

Clinical exposure to Rh-irAEs remains low; 80% of respondents had never managed a related case. Among the 21% who had clinical experience, the median number of cases seen was only two. The most common manifestations reported were inflammatory arthritis (50%), followed by myositis (17.4%) and skin reactions (13%).

Crucially, not a single respondent felt "completely confident" in managing these conditions. Over half (56.5%) reported being "not confident at all," a sentiment that persisted even when advising oncology colleagues on the critical decision of whether to continue or suspend ICI therapy during toxicity.

Treatment Variability

Among practitioners who had treated Rh-irAEs, there was no consensus on therapeutic approach. Initial treatments varied widely, ranging from NSAIDs to aggressive combinations of corticosteroids and methotrexate. Long-term management was similarly inconsistent, utilizing various biologic agents such as TNF inhibitors.

Discussion and Future Directions

The primary limitation of this study is the low response rate (3.3%), which may introduce selection bias. Furthermore, the cohort was heavily weighted toward North American academic centers (81%), potentially limiting the generalizability of the findings to community-based or international settings.

Despite these limitations, the data underscores a massive appetite for professional education, with 91.3% of respondents willing to participate in targeted learning activities. To bridge the identified gaps, the authors propose:

  1. Pediatric-Specific Guidelines: Developing consensus-based clinical practice guidelines tailored to the developing immune systems of children.
  2. Interdisciplinary Collaboration: Strengthening partnerships between oncology and rheumatology to create shared decision-making frameworks.
  3. Targeted Education: Implementing online modules, webinars, and conference sessions focused on the acute and long-term management of Rh-irAEs.

As ICIs become a mainstay in pediatric oncology, the rheumatology community must proactively prepare for the increasing prevalence of these complex side effects.

Summary updated

Abstract

Significant knowledge gaps and a lack of confidence exist among PRs managing ICI-related Rh-irAEs. As ICI use increases in pediatric oncology, PRs' exposure to Rh-irAEs will follow. Targeted educational programs and clinical guidelines may be valuable to address these gaps.
BibTeX
@inproceedings{storwick2025immune,
  author = {John Storwick and Carrie Ye and Shahin Jamal and Nancy Maltez and Mercedes Chan},
  title = {{Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment}},
  booktitle = {Pediatric},
  year = {2025},
  doi = {10.1186/s12969-025-01127-x},
}
Figure